Your search for oral corticosteroids returned 40 results

Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.

The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…

A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.

What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?

Asthma control as measured by AIRQ may predict 12-month HRQoL, according to research reported at the 2021 ACAAI Annual Scientific Meeting.

The CLEAR study compared clinical outcomes and health resource usage in patients with severe asthma who continued, switched, or stopped their biologic treatment.

Study authors conducted a prospective randomized trial to determine if there is a role for oral steroids in patients who have CRSsNP.

The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Findings may help with decision-making in this high-risk patient population.

The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.